Pfizer, Alnylam, BridgeBio gain after late-stage trial setback for Astra/ Ionis
Seeking Alpha ·
Pfizer ( PFE ), Alnylam Pharma ( ALNY ), and BridgeBio Pharma ( BBIO ), which market drugs for a rare heart condition known as ATTR-CM, are on the rise in the premarket on Thursday after AstraZeneca ( AZN ) and
DYAX Investor Sentiment
Bullish (Long) 44% · Bearish (Short) 56%
536 participants
Related News
- Trump 2.0 is outperforming historical presidential market cycles
- ClearBridge Global Infrastructure Income Strategy adds DTM; exits PEG, MAQAF, SSEZF
- European Commission finds Meta's Facebook and Instagram to be addictive
- Jiuzi Holdings plans cooperation with AI imaging and data platform company
- Applied Materials, Lam, KLA take advantage of prolonged demand cycle: Stifel
- CNBC’s Jim Cramer sees value in SK Hynix despite chip cycle risk